RESUMO
Studies have investigated the effects of androgen deprivation therapy (ADT) use on the incidence and clinical outcomes of coronavirus disease 2019 (COVID-19); however, the results have been inconsistent. We searched the PubMed, Medline, Cochrane, Scopus, and Web of Science databases from inception to March 2022; 13 studies covering 84 003 prostate cancer (PCa) patients with or without ADT met the eligibility criteria and were included in the meta-analysis. We calculated the pooled risk ratios (RRs) with 95% confidence intervals (CIs) to explore the association between ADT use and the infection risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and severity of COVID-19. After synthesizing the evidence, the pooled RR in the SARS-CoV-2 positive group was equal to 1.17, and the SARS-CoV-2 positive risk in PCa patients using ADT was not significantly different from that in those not using ADT (P = 0.544). Moreover, no significant results concerning the beneficial effect of ADT on the rate of intensive care unit admission (RR = 1.04, P = 0.872) or death risk (RR = 1.23, P = 0.53) were found. However, PCa patients with a history of ADT use had a markedly higher COVID-19 hospitalization rate (RR = 1.31, P = 0.015) than those with no history of ADT use. These findings indicate that ADT use by PCa patients is associated with a high risk of hospitalization during infection with SARS-CoV-2. A large number of high quality studies are needed to confirm these results.
Assuntos
Masculino , Humanos , Neoplasias da Próstata/induzido quimicamente , Antagonistas de Androgênios/efeitos adversos , COVID-19 , Androgênios/uso terapêutico , SARS-CoV-2RESUMO
Abstract n our study, we aimed to validate a method based on liquid chromatography-mass spectrometry (LC-MS) to quantify spironolactone (SPI) and its active metabolite canrenone (CAN) simultaneously in plasma samples to support in vivo experiments. Compounds were separated by using a C18 column with the isocratic elution of a mobile phase composed of 0.1% (v/v) formic acid in methanol-water (60:40 v/v) at a flow rate of 0.4 mL min−1. SPI and CAN were detected in na electrospray interface operating in a positive ionization mode and quantified using the selective ion mode monitoring of mass-charge ratios (m/z) of 439.0 for SPI and 363.1 for CAN. After calculating the matrix effect using theoretical equations, we observed the strong interference of plasma in the equipment-generated signal, which required creating analytical curves using the matrix as a solvent. The method was nevertheless linear (r 2 > 0.999) in a concentration range of 0.4-5.0 µg mL−1, as well as precise, with a coefficient of variation less than 5%. SPI's and CAN's recovery rates from the plasma ranged from 87.4% to 112.1%, while their limits of detection (i.e., 0.07 µg mL−1 and 0.03 µg mL−1, respectively) and quantification (i.e., 0.20 µg mL−1 and 0.08 µg mL−1, respectively) in the presence of plasma contaminants were low. Therefore, the bioanalytical method seems to be feasible for quantifying SPI and CAN in plasma
Assuntos
Plasma , Espectrometria de Massas/métodos , Espironolactona/análise , Canrenona/análise , Cromatografia Líquida/métodos , Farmacocinética , Antagonistas de Androgênios/efeitos adversosRESUMO
Ethnicity might be associated with treatment outcomes in advanced prostate cancer. This study aimed to evaluate the efficacy and safety of androgen deprivation therapy (ADT) combined with apalutamide in East Asians with metastatic castration-sensitive prostate cancer (mCSPC). The original phase 3 Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) trial was conducted at 260 sites in 23 countries. This subgroup analysis included patients enrolled in 62 participating centers in China, Japan, and Korea. Radiographic progression-free survival (PFS), time to prostate-specific antigen (PSA) progression, and PSA changes from baseline were compared between groups in the East Asian population. The intent-to-treat East Asian population included 111 and 110 participants in the apalutamide and placebo groups, respectively. The 24-month radiographic PFS rates were 76.1% and 52.3% in the apalutamide and placebo groups, respectively (apalutamide vs placebo: hazard ratio [HR] = 0.506; 95% confidence interval [CI], 0.302-0.849; P = 0.009). Median time to PSA progression was more favorable with apalutamide than placebo (HR = 0.210; 95% CI, 0.124-0.357; P < 0.001). Median maximum percentages of PSA decline from baseline were 99.0% and 73.9% in the apalutamide and placebo groups, respectively. The most common adverse event (AE) was rash in the apalutamide group, with a higher rate than that in the placebo group (37.3% vs 9.1%). The most common grade 3 or 4 AEs were rash (12 [10.9%]) and hypertension (12 [10.9%]) for apalutamide. The efficacy and safety of apalutamide in the East Asian subgroup of the TITAN trial are consistent with the global results.
Assuntos
Humanos , Masculino , Antagonistas de Androgênios/efeitos adversos , Exantema/induzido quimicamente , Ásia Oriental , Antígeno Prostático Específico , Neoplasias de Próstata Resistentes à Castração/patologia , Tioidantoínas/efeitos adversosRESUMO
SUMMARY OBJECTIVE: To analyze the mortality trend of young men who were victims of traffic injuries involving motorcycles in all Brazilian capitals from 2001 to 2015. METHODS: A time-series study on all deaths of men aged 20-39 years old due to traffic injuries involving motorcycles in all 27 Brazilian capitals. We used the joinpoint regression model for temporal analysis and calculated the Annual Percent Change (APC) and Average Annual Percent Change (AAPC) to verify the mortality trends. RESULTS: A total of 12,058 deaths of young men were recorded in the Brazilian capitals during the period studied. The highest mortality rates were observed in Boa Vista/Roraima (34.0/100,000 population) and Palmas/Tocantins (29.80/100,000). Twelve of the 27 capitals showed an increasing trend in mortality, with the highest percentage increase being observed in Salvador (APC: 29.0%) and São Paulo (APC: 13.1%). None of the capitals showed a decline in the trend of mortality. CONCLUSIONS: Overall, the mortality of young men from traffic injuries involving motorcycles shows an increasing trend in 12 of the 27 capitals, which represents a public health problem that requires the implementation of more effective public policies.
RESUMO OBJETIVO: Analisar a tendência temporal da mortalidade de homens jovens vítimas de acidente de trânsito envolvendo motocicletas em todas as capitais brasileiras de 2001 a 2015. MÉTODOS: Estudo de séries temporais incluindo as mortes de homens de 20 a 39 anos por lesões no trânsito envolvendo motocicletas nas 27 capitais brasileiras. Para a análise, foi utilizado o modelo de regressão do ponto de inflexão e calculada a Variação Percentual Anual (APC) e a Variação Percentual Anual Média (AAPC). RESULTADOS: Foram registradas 12.058 mortes de homens jovens nas capitais brasileiras durante o período estudado. As maiores taxas de mortalidade foram observadas em Boa Vista/Roraima (34,0/100.000 habitantes) e Palmas/Tocantins (29,80/100.000). Doze capitais apresentaram tendência crescente de mortalidade, sendo o maior aumento percentual em Salvador (APC: 29,0%) e São Paulo (APC: 13,1%). Nenhuma das capitais mostrou declínio nas taxas. CONCLUSÕES: A mortalidade de jovens por lesões no trânsito envolvendo motocicletas tem mostrado uma tendência crescente em 12 capitais, o que representa um problema de saúde pública que requer a implementação de políticas públicas mais eficazes.
Assuntos
Humanos , Masculino , Pneumonia Viral , Neoplasias da Próstata/tratamento farmacológico , Infecções por Coronavirus , Pandemias , Antagonistas de Androgênios/efeitos adversos , BetacoronavirusRESUMO
Las mujeres han sido tratadas por décadas con testosterona intentando aliviar una gran variedad de síntomas con riesgos y beneficios inciertos. En la mayoría de los países, la testosterona se prescribe "off-label", de modo que las mujeres están utilizando compuestos y dosis ideadas para tratamientos en hombres. En este sentido, varias sociedades médicas de distintos continentes adoptaron recientemente por consenso una toma de posición sobre los beneficios y potenciales riesgos de la terapia con testosterona en la mujer, explorar las áreas de incertidumbre e identificar prácticas de prescripción con potencial de causar daño. Las recomendaciones con respecto a los beneficios y riesgos de la terapia con testosterona se basan en los resultados de ensayos clínicos controlados con placebo de al menos 12 semanas de duración. A continuación se comentan las recomendaciones. (AU)
There are currently no clear established indications for testosterone replacement therapy for women. Nonetheless, clinicians have been treating women with testosterone to alleviate a variety of symptoms for decades with uncertainty regarding its benefits and risks. In most countries, testosterone therapy is prescribed off-label, which means that women are using testosterone formulations or compounds approved for men with a modified dose for women. Due to these issues, there was a need for a global Consensus Position Statement on testosterone therapy for women based on the available evidence from placebo randomized controlled trials (RCTs). This Position Statement was developed to inform health care professionals about the benefits and potential risks of testosterone therapy intended for women. The aim of the Consensus was to provide clear guidance as to which women might benefit from testosterone therapy; to identify symptoms, signs, and certain conditions for which the evidence does not support the prescription of testosterone; to explore areas of uncertainty, and to identify any prescribing practices that have the potential to cause harm. (AU)
Assuntos
Humanos , Feminino , Idoso , Testosterona/uso terapêutico , Pós-Menopausa/efeitos dos fármacos , Depressores do Apetite/efeitos adversos , Fenitoína/efeitos adversos , Placebos/administração & dosagem , Psicotrópicos/efeitos adversos , Tamoxifeno/efeitos adversos , Testosterona/administração & dosagem , Testosterona/análise , Testosterona/efeitos adversos , Testosterona/farmacologia , Fármacos Cardiovasculares/efeitos adversos , Indometacina/efeitos adversos , Hormônio Liberador de Gonadotropina/efeitos adversos , Pós-Menopausa/fisiologia , Ensaios Clínicos Controlados como Assunto , Antagonistas Colinérgicos/efeitos adversos , Anticoncepcionais Orais/efeitos adversos , Disfunções Sexuais Psicogênicas/etiologia , Disfunções Sexuais Psicogênicas/terapia , Danazol/efeitos adversos , Consenso , Inibidores da Aromatase/efeitos adversos , Uso Off-Label , Inibidores do Fator Xa/efeitos adversos , Anfetaminas/efeitos adversos , Antagonistas dos Receptores Histamínicos/efeitos adversos , Antagonistas de Androgênios/efeitos adversos , Androgênios/fisiologia , Cetoconazol/efeitos adversos , Entorpecentes/efeitos adversosRESUMO
The aim of the present study was to determine whether oncologic outcomes and adverse events associated with active on/off intermittent antiandrogen monotherapy (daily bicalutamide, 50 mg per day) are comparable with those of standard external beam radiation therapy (EBRT) or combined androgen blockade (CAB) therapy in prostate cancers with positive surgical margins after radical prostatectomy. Two hundred twenty-three patients with positive surgical margins post-radical prostatectomy who underwent active surveillance (AS, n = 32), EBRT without hormone therapy (n = 55), intermittent antiandrogen monotherapy without EBRT (IAAM, n = 50), or CAB without EBRT (n = 86), between 2007 and 2014, were reviewed retrospectively. Pathologic outcomes, biochemical recurrence rates, radiological disease progression, and adverse events were collected from medical records. Biochemical recurrence rates, biochemical recurrence-free survival rates, and radiological recurrence were not different between the groups (P = 0.225, 0.896, and 0.284, respectively). Adverse event rates and severities were lower for IAAM compared with EBRT or CAB (both P < 0.05), but were comparable to those for AS (P = 0.591 and 0.990, respectively). Grade ≥3 adverse events were not reported in the IAAM or AS groups. Erectile dysfunction and loss of libido rates were lower in the IAAM group compared with the EBRT and CAB groups (P = 0.032). Gastrointestinal complications were more frequently reported in the EBRT group (P = 0.008). Active on/off IAAM treatment might be an appropriate treatment option for patients with positive surgical margins after radical prostatectomy. Furthermore, regarding oncologic outcomes, IAAM was comparable to standard EBRT but had a milder adverse event profile.
Assuntos
Idoso , Idoso de 80 Anos ou mais , Humanos , Masculino , Antagonistas de Androgênios/efeitos adversos , Anilidas/efeitos adversos , Antineoplásicos/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Quimioterapia Adjuvante/efeitos adversos , Intervalo Livre de Doença , Recidiva Local de Neoplasia/sangue , Neoplasia Residual , Nitrilas/efeitos adversos , Antígeno Prostático Específico/sangue , Prostatectomia , Neoplasias da Próstata/terapia , Radioterapia Adjuvante/efeitos adversos , Estudos Retrospectivos , Compostos de Tosil/efeitos adversosRESUMO
Maximum androgen blockade is the standard endocrine treatment for advanced prostate cancer. Interstitial lung disease in different degrees of severity, with low mortality and excellent response to treatment may appear with its use. We report a 77 years old patient with advanced prostate cancer who developed severe and progressive respiratory failure associated to bilateral pulmonary infiltrates, attributed to the direct effect of maximum androgen blockade. Despite the therapeutic efforts, the patient died. Lung pathology revealed Usual Interstitial Pneumonia.
Assuntos
Humanos , Masculino , Idoso , Doenças Pulmonares Intersticiais/induzido quimicamente , Antagonistas de Androgênios/efeitos adversos , Antinematódeos/efeitos adversos , Neoplasias da Próstata/tratamento farmacológico , Compostos de Tosil/efeitos adversos , Biópsia , Adenocarcinoma/tratamento farmacológico , Tomografia Computadorizada por Raios X , Doenças Pulmonares Intersticiais/patologia , Evolução Fatal , Progressão da Doença , Anilidas/efeitos adversos , Nitrilas/efeitos adversosRESUMO
Introducción: el cáncer de próstata (CP) es el tumor maligno más frecuente en hombres en Uruguay. La terapia de deprivación androgénica (TDA) es una herramienta valiosa para su tratamiento. Si bien es altamente eficaz, este tratamiento tiene diversos efectos no deseados, entre los que se encuentra la disminución de la densidad mineral ósea. Material y método: realizamos un estudio longitudinal, observacional y prospectivo cuyo objetivo fue determinar si existe disminución de la densidad mineral ósea en los pacientes que reciben TDA para el CP. Se incluyeron pacientes portadores de CP en cualquier estadio que iniciarían tratamiento con TDA en el Servicio de Oncología del Hospital de Clínicas de Montevideo, Uruguay, en el período setiembre de 2012 a agosto de 2013, en quienes se realizó una densitometría ósea (DMO) previo al inicio de la TDA (DMO1) y se repitió a los seis meses de recibir la primera dosis de tratamiento hormonal (DMO2). Para cada región analizada se compararon las medias de densidad ósea medida en g/cm2 en la DMO1 vs DMO2. Resultados: se hizo seguimiento a diez pacientes con una edad mediana de 77 años. Se observó disminución significativa de la densidad mineral ósea en vértebras L3 y L4 (L3: 1.268 g/cm2 a 1.225 g/cm2 p=0,01; L4: 1.247 g/cm2 a 1.227g/cm2 p=0,005), mientras que en los otros puntos evaluados (L1, L2, cuello de fémur y cadera total) también hubo una disminución pero sin alcanzar significancia estadística. Conclusiones: confirmamos que la TDA disminuye la densidad mineral ósea por lo menos en vértebras lumbares 3 y 4 en un relativamente corto plazo (seis meses). Este efecto adverso debe evaluarse, identificarse y prevenirse oportunamente para evitar complicaciones mayores.
Abstract Introduction: prostate cancer is the most frequent malignant tumor in men in Uruguay. Androgenic deprivation therapy (ADT) is a valuable tool to treat this condition. In spite of it being highly effective, this treatment has several non-desirable effects, a reduction in bone mineral density being among them. Material: we conducted a longitudinal, observational and prospective study whose objective was to determine whether there is a reduction in bone mineral density in patients who receive ADT for prostate cancer. Patients who were carriers of prostate cancer undergoing any stage who would start their ADT treatment at the Oncology Unit of the University Hospital of Montevideo from September 2012 through August 2013 were included in the study. All of them underwent a bone densitometry prior to the initiation of ADT (BD1) treatment and it was repeated six months after they received the first dose of hormone treatment (BD2). Measurements of bone density were compared for every region analysed in g/ cm2 in BD1 versus BD2. Results: Ten patients with an average age of 77 years old were followed-up. A significant reduction in bone mineral density was observed in the L3-L4 spinal segment (L3: 1.268 g/cm2 at 1.225 g/cm2 p=0.01; L4: 1.247g/cm2 at 1.227g/cm2 p=0.005), whereas in the other points assessed (L1, L2, femoral neck and total hip) there was a reduction as well, although it did not represent any statistical significance. Conclusions: we confirmed ADT reduces the bone mineral density in lumbar vertebrae L3 and L4 in a relatively short time (six minths). This negative effect needs to be timely assessed, identified and prevented to avoid greater complications.
Resumo Introdução: o câncer de próstata (CP) é o tumor maligno mais frequente em homens no Uruguai. A terapia de deprivação androgênica (TDA) é uma ferramenta valiosa para seu tratamento. Embora seja altamente eficaz, este tratamento apresenta diversos efeitos não desejados, entre eles a diminuição da densidade mineral óssea. Material e método: realizamos um estudo longitudinal, observacional e prospectivo cujo objetivo foi detectar uma possível redução da densidade mineral óssea em pacientes que recebem TDA para CP. Foram incluídos pacientes portadores de CP em qualquer estadio que iniciaram tratamento com TDA no Serviço de Oncologia do Hospital de Clínicas de Montevidéu, Uruguai, no período setembro de 2012 a agosto de 2013; antes do inicio do tratamento foi realizada una densitometria óssea (DMO1) e uma segunda seis meses depois da primeira dose de tratamento hormonal (DMO2). Para cada região analisada foram comparadas as medias de densidade óssea medida en g/cm2 na DM1 versus DMO2. Resultados: dez pacientes com um mediana de idade de 77 anos foram estudados. Observamos uma diminuição significativa da densidade mineral óssea nas vértebras L3 e L4 (L3: 1.268 g/cm2 a 1.225 g/cm2 p=0,01; L4: 1.247g/cm2 a 1.227g/cm2 p=0,005); em outros pontos avaliados (L1, L2, colo de fêmur e quadril total) também houve diminuição porém não era estatisticamente significativa. Conclusões: confirmamos que a TDA diminui a densidade mineral óssea pelo menos nas vértebras lombares 3 e 4 em um prazo relativamente curto (seis meses). Este efeito adverso deve ser avaliado, identificado e prevenido oportunamente para evitar maiores complicações.
Assuntos
Masculino , Neoplasias da Próstata/tratamento farmacológico , Neoplasias da Próstata/terapia , Densidade Óssea , Antineoplásicos Hormonais/efeitos adversos , Antagonistas de Androgênios/efeitos adversosRESUMO
The therapeutic effects and side effects of androgen deprivation therapy (ADT), which is a main treatment method for metastatic prostate cancer, are well known, but the metabolic effects have only recently been studied. This review describes the effects of ADT on body habitus, insulin resistance, lipid profiles, diabetes, metabolic syndrome, and cardiovascular morbidity and mortality. The review was done by using KoreaMed and PubMed to search the medical literature related to prostate cancer, ADT, body habitus, lipid profile, diabetes, insulin resistance, metabolic syndrome, and cardiovascular disease. ADT increases fat mass and decreases lean body mass. Fat mostly accumulates in the subcutaneous area. ADT increases total cholesterol, triglycerides, and high-density lipoprotein, as well as the risk for insulin resistance and diabetes. ADT also increases the risk for cardiovascular events, but insufficient evidence is available for a correlation with mortality. ADT changes body habitus and lipid profiles and has different characteristics than those of classic metabolic syndrome, but it is related to insulin resistance and diabetes. ADT increases the risk for cardiovascular events. No consistent guidelines have been proposed for treating the metabolic effects of ADT, but the generally recommended treatment methods for lowering the risk of diabetes and cardiovascular disease should be fully understood. Additional studies are necessary.
Assuntos
Humanos , Masculino , Antagonistas de Androgênios/efeitos adversos , Composição Corporal/efeitos dos fármacos , Doenças Cardiovasculares/metabolismo , Colesterol/química , Diabetes Mellitus/epidemiologia , Hormônio Liberador de Gonadotropina/agonistas , Resistência à Insulina , Lipídeos/sangue , Lipoproteínas HDL/sangue , Síndrome Metabólica/epidemiologia , Neoplasias da Próstata/tratamento farmacológico , Fatores de Risco , Triglicerídeos/químicaRESUMO
Objectives: To review the literature and present new data of continuous androgen deprivation therapy (ADT) vs intermittent androgen deprivation (IAD) as therapies for prostate cancer in terms of survival and quality of life and clarify practical issues in the use of IAD. Materials and Methods: We conducted a systematic search on Medline and Embase databases using “prostatic neoplasm” and “intermittent androgen deprivation” as search terms. We reviewed meta-analyses, randomised controlled trials, reviews, clinical trials and practise guidelines written in English from 2000 and onwards until 01/04/2013. Ten randomized controlled trials were identified. Seven of them published extensive data and results randomizing 4675 patients to IAD versus CAD. Data from the other three randomized trials were limited. Results: Over the last years studies confirmed that IAD is an effective alternative approach to hormonal deprivation providing simultaneously several potential benefits in terms of quality of life and cost effectiveness. Thus, in patients with non metastatic, advanced prostate cancer IAD could be used as standard treatment, while in metastatic prostate cancer IAD role still remains ambiguous. Conclusions: Nowadays, revaluation of the gold standard of ADT in advanced prostate cancer appears essential. Recent data established that IAD should no longer be considered as investigational, since its effectiveness has been proven, especially in patients suffering from non-metastatic advanced prostate cancer. .
Assuntos
Humanos , Masculino , Antagonistas de Androgênios/administração & dosagem , Antineoplásicos Hormonais/administração & dosagem , Neoplasias da Próstata/tratamento farmacológico , Antagonistas de Androgênios/efeitos adversos , Antineoplásicos Hormonais/efeitos adversos , Esquema de Medicação , Antígeno Prostático Específico/sangue , Qualidade de Vida , Reprodutibilidade dos Testes , Fatores de Tempo , Resultado do TratamentoRESUMO
O adenocarcinoma de próstata é o câncer mais comum no sexo masculino após o câncer de pele. Entre as várias formas de tratamento do câncer de próstata, a terapia de bloqueio androgênico é uma modalidade consagrada nos pacientes com doença metastática ou localmente avançada, que provavelmente resulta em aumento de sobrevida. No entanto, o bloqueio androgênico é causador de uma série de consequências adversas. Complicações como osteoporose, disfunção sexual, ginecomastia, anemia e alterações na composição corporal são bem conhecidas. Recentemente, uma série de complicações metabólicas foi descrita como aumento da circunferência abdominal, resistência à insulina, hiperglicemia, diabete, dislipidemia e síndrome metabólica com consequente aumento do risco de eventos coronarianos e mortalidade cardiovascular nessa população específica. Este artigo de atualização apresenta uma revisão bibliográfica realizada no MEDLINE de toda literatura publicada em inglês no período de 1966 até junho de 2009, com as seguintes palavras-chave: androgen deprivation therapy, androgen supression therapy, hormone treatment, prostate cancer, metabolic syndrome e cardiovascular disease, no intuito de analisar quais seriam os reais riscos cardiovasculares da terapia de deprivação androgênica, também chamada bloqueio androgênico, nos pacientes com câncer de próstata.
El adenocarcinoma de próstata es el cáncer más común en el sexo masculino después del cáncer de piel. Entre las varias formas de tratamiento del cáncer de próstata, la terapia de bloqueo androgénico es una modalidad consagrada en los pacientes con enfermedad metastásica o localmente avanzada, que probablemente resulta en aumento de sobrevida. Mientras tanto, el bloqueo androgénico es causante de una serie de consecuencias adversas. Complicaciones como osteoporosis, disfunción sexual, ginecomastia, anemia y alteraciones en la composición corporal son bien conocidas. Recientemente, una serie de complicaciones metabólicas fue descripta como aumento de la circunferencia abdominal, resistencia a la insulina, hiperglicemia, diabetes, dislipidemia y síndrome metabólico con consecuente aumento del riesgo de eventos coronarios y mortalidad cardiovascular en esa población específica. Este artículo de actualización presenta una revisión bibliográfica realizada en el MEDLINE de toda literatura publicada en inglés en el período de 1966 hasta junio de 2009, con las siguientes palabras-clave: androgen deprivation therapy, androgen supression therapy, hormone treatment, prostate cancer, metabolic syndrome y cardiovascular disease, con el propósito de analizar cuales serían los reales riesgos cardiovasculares de la terapia de deprivación androgénica, también llamada bloqueo androgénico, en los pacientes con cáncer de próstata.
Prostate adenocarcinoma is the most common cancer type in the male sex after skin cancer. Among the several types of treatment for prostate cancer, the androgen deprivation therapy has been highly recommended in patients with metastatic or locally advanced disease, which probably results in increased survival. However, the androgen deprivation is the cause of several adverse effects. Complications such as osteoporosis, sexual dysfunction, gynecomastia, anemia and body composition alterations are well-known effects of the therapy. Recently, a number of metabolic complications have been described, such as increase in the abdominal circumference, insulin resistance, hyperglycemia, diabetes, dyslipidemia and metabolic syndrome, with a consequent increase in the risk of coronary events and cardiovascular mortality in this specific population. This update article presents a literature review carried out at MEDLINE database of all literature published in English from 1966 to June 2009, using the following key words: androgen deprivation therapy, androgen suppression therapy, hormone treatment, prostate cancer, metabolic syndrome and cardiovascular disease, with the objective of analyzing which would be the actual cardiovascular risks of androgen deprivation therapy, also called androgen suppression, in patients with prostate cancer.
Assuntos
Humanos , Masculino , Antagonistas de Androgênios/efeitos adversos , Antineoplásicos Hormonais/efeitos adversos , Doenças Cardiovasculares/induzido quimicamente , Neoplasias da Próstata/tratamento farmacológico , Adenocarcinoma/tratamento farmacológico , Fatores de RiscoRESUMO
PURPOSE: Recent work has demonstrated the return of hormone sensitivity after palliative chemotherapy in androgen independent prostate cancer. We wished to establish whether a similar phenomenon existed in patients with no exposure to chemotherapy. MATERIALS AND METHODS: A review of hormone resistant patients who had received salvage brachytherapy for localized prostate cancer after previous external beam radiotherapy was undertaken. Three patients with subsequent biochemical relapse responded to the rechallenge with hormonal treatment. RESULTS: The series of patients presented here demonstrates this phenomenon occurs after salvage brachytherapy with no exposure to chemotherapy. Recovery of sensitivity is demonstrated both to androgen deprivation and to androgen receptor antagonism. The recovery of hormone sensitivity was surprisingly durable, ranging from eight months to over twenty-one months. CONCLUSIONS: Hormone sensitivity may be recovered after salvage brachytherapy. Potential mechanisms underlying these observations are discussed and the likely central role of the activity of the androgen receptor highlighted. The relevance of these findings to the management of advanced prostate cancer is considered including thoughts on the practice of intermittent anti-androgen therapy.
Assuntos
Idoso , Humanos , Masculino , Pessoa de Meia-Idade , Braquiterapia/métodos , Recidiva Local de Neoplasia/radioterapia , Neoplasias da Próstata/radioterapia , Antagonistas de Androgênios/efeitos adversos , Antígeno Prostático Específico/sangue , Neoplasias da Próstata/tratamento farmacológico , Receptores Androgênicos/fisiologia , Terapia de SalvaçãoRESUMO
OBJECTIVE: To assess the prevalence, onset, duration and severity of hot flashes in men after bilateral orchidectomies (BO) for prostate cancer, to evaluate body temperature changes during hot flashes and to determine whether an elevated temperature within a few days after BO can be caused by deprivation of androgen. MATERIALS AND METHODS: Patients (n = 101) were questioned about the characteristics of their hot flashes after BO for prostate cancer. A subgroup of these men (n = 17) were instructed to record their oral and forehead temperatures during and at fixed intervals between hot flashes daily for 4 weeks. RESULTS: The mean age was 71.6 years, mean follow-up after BO was 33.2 months. Hot flashes were reported by 87 men (86 percent) with previous spontaneous remission in 9 (10 percent). The median time between BO and the onset of hot flashes was 21 days (range 1-730), median number of hot flashes 3 per day (range 1-20), and median duration was 120 seconds (range 5 to 1800). There was no significant difference between median oral (36.4º C) and forehead (36.0º C) temperature in the normal state, but during hot flashes the median forehead temperature (37.0º C) was higher than the oral temperature (36.5º C) (p = 0.0004). Both median oral and forehead temperatures were higher during hot flashes (36.5º C and 37.0º C) than in the normal state (36.4º C and 36.0º C, respectively) (p < 0.0001). During hot flashes, the oral temperature was 38º C to 40º C in only 3.2 percent of 593 readings in 17 patients. CONCLUSIONS: The median oral and forehead temperatures are higher during hot flashes than in normal periods. Oral temperature elevation > 38º C within days after a BO is unlikely to be the result of androgen deprivation alone.
Assuntos
Idoso , Idoso de 80 Anos ou mais , Humanos , Masculino , Pessoa de Meia-Idade , Antagonistas de Androgênios/efeitos adversos , Fogachos/etiologia , Orquiectomia/efeitos adversos , Neoplasias da Próstata/cirurgia , Temperatura Corporal , Seguimentos , Fogachos/induzido quimicamente , Neoplasias da Próstata/tratamento farmacológico , Qualidade de Vida , Índice de Gravidade de Doença , Estatísticas não Paramétricas , Fatores de TempoRESUMO
Different perturbations during fetal and post natal development unleash endocrine adaptations that permanently alter metabolism, increasing the susceptibility to develop later disease, process known as "developmental programming"'. Endocrine disruptor compounds (EDC) are widely spread on the environment and display estrogenic, anti-estrogenic or anti-androgenic activity; they are lypophilyc and stored for long periods on the adipose tissue. Maternal exposure to EDC during pregnancy and lactation produces the exposure of the fetus and neonate through placenta and breast milk. Epidemiological and experimental studies have demonstrated reproductive alterations as a consequence of intrauterine and/or neonatal exposure to EDC. Diethystilbestrol (DES) is the best documented compound, this synthetic estrogen was administered to pregnant women at the BO and 60 to prevent miscarriage. It was implicated in urogenital abnormalities in children exposed in utero and withdrawn from the market. The "DES daughters" are women with high incidence of vaginal hypoplasia, spontaneous abortion, premature delivery, uterine malformation, menstrual abnormalities and low fertility. The "DES sons" show testicular dysgenesis syndrome, which is characterized by hypospadias, cryptorchidism and low semen quality. This entity is also associated to the fetal exposure to anti-androgens as flutamide. The effects on the reproductive axis depend on the stage of development and the window of exposure, as well as the dose and the compound. The wide distribution of EDC into the environment affects both human health and ecosystems in general, the study of their mechanisms of action is extremely important currently.
Diversas perturbaciones durante el desarrollo fetal y posnatal desencadenan adaptaciones endocrinas que modifican permanentemente el metabolismo, incrementando la susceptibilidad para el desarrollo de enfermedades, proceso conocido como "programación durante el desarrollo". Los compuestos disruptores endocrinos (CDE) se encuentran en el medio ambiente y presentan actividad estrogénica, antiestrogénica o antiandrogénica; son altamente lipofílicos y se almacenan por periodos prolongados en el tejido adiposo. La exposición materna a CDE durante el embarazo y la lactancia permite su paso al producto a través de la placenta y la leche materna. Estudios epidemiológicos y experimentales han demostrado alteraciones en el eje reproductivo como consecuencia de la exposición intrauterina y/o neonatal a CDE. El compuesto mejor documentado es el dietilestilbestrol (DES), este estrógeno sintético fue administrado a mujeres embarazadas durante los 50s y 60s y retirado del mercado por su implicación en anormalidades urogenitales de los bebés expuestos in útero. Las denominadas "hijas del DES" son mujeres con alta incidencia de hipoplasia vaginal, malformaciones uterinas, irregularidades menstruales, baja fertilidad y alta prevalencia de aborto espontáneo y parto prematuro. Por su parte, "los hijos del DES" presentan una entidad clínica conocida como síndrome de disgenesia testicular caracterizado por hipospadias, criptorquidia y baja calidad del semen. Este síndrome también se asocia a la exposición fetal a compuestos antiandrogénicos como la ñutamida. Los efectos en el eje reproductivo dependen del estadio de desarrollo y del tiempo de exposición, así como de la dosis y el compuesto del que se trate. La extensa presencia de CDE en el ambiente afecta la salud humana e impacta al ecosistema en general por lo cual es de suma importancia el estudio de los mecanismos involucrados en su acción.
Assuntos
Adulto , Animais , Feminino , Humanos , Masculino , Gravidez , Ratos , Anormalidades Induzidas por Medicamentos/etiologia , Disruptores Endócrinos/efeitos adversos , Genitália/efeitos dos fármacos , Efeitos Tardios da Exposição Pré-Natal , Anormalidades Induzidas por Medicamentos/epidemiologia , Antagonistas de Androgênios/efeitos adversos , Antagonistas de Androgênios/farmacologia , Mama/embriologia , Dietilestilbestrol/efeitos adversos , Dietilestilbestrol/farmacologia , Dietilestilbestrol/uso terapêutico , Dioxinas/efeitos adversos , Desenvolvimento Embrionário/efeitos dos fármacos , Disruptores Endócrinos/farmacologia , Antagonistas de Estrogênios/efeitos adversos , Antagonistas de Estrogênios/farmacologia , Estrogênios/agonistas , Feminização/induzido quimicamente , Feminização/embriologia , Genitália/anormalidades , Genitália/embriologia , Hipotálamo/anormalidades , Hipotálamo/efeitos dos fármacos , Hipotálamo/embriologia , Glândulas Mamárias Animais/embriologia , Leite Humano/química , Ácidos Ftálicos/efeitos adversos , Fitoestrógenos/efeitos adversos , Fitoestrógenos/farmacologia , Fitoestrógenos/uso terapêutico , Virilismo/induzido quimicamente , Virilismo/embriologiaRESUMO
Background : Gynecomastia can be physiological or pathological. A limited study of gynecomastia is recommended during puberty and in the elderly, ages in which gynecomastia is usually considered physiological. Other authors suggest that this condition should be studied when it is painful, rapidly growing, of recent onset, when its diameter is more than 4 cm and when is associated to testicular masses. Aim: To investigate the causes of gynecomastia and to evaluate the above mentioned criteria to exclude pathological conditions. Material and methods: Prospective study of 117 patients aged 10 to 83 years, consulting for gynecomastia. All were subjected to a standardized study including a clinical examination and measurement of plasma estradiol and testosterone levels. Results: Forty one percent of gynecomastias were considered pathological and the rest, physiological. Among pathological conditions, 18 patients had an endocrine etiology (hypogonadism in ten patients, estrogen secreting tumors in three, hyperestrogenism of unknown etiology in four and peripheral resistance to androgens in one), in 17 it was secondary to medications and in 13 it was secondary to other causes (idiopathic, pesticide exposure, alcoholism, diabetes or re feeding). In 79 percent of 86 patients of less than 20 years, the condition was physiological and in four of five elderly subjects, it was pathological. Thirty nine percent of pathological gynecomastias lacked the signs and symptoms that according to authors, should prompt a thorough study. Conclusions: All patients with gynecomastia should be studied with a complete medical history and the measurement of estradiol and testosterone levels. The criteria proposed to conduct minimal studies in gynecomastia, would miss a large volume of pathological conditions.
Assuntos
Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Humanos , Masculino , Pessoa de Meia-Idade , Ginecomastia/etiologia , Antagonistas de Androgênios/efeitos adversos , Estradiol/efeitos adversos , Estradiol/sangue , Estrogênios/efeitos adversos , Estrogênios/sangue , Ginecomastia/sangue , Ginecomastia/fisiopatologia , Hipogonadismo/complicações , Estudos Prospectivos , Testosterona/sangueRESUMO
A 41-year-old woman, who was on flutamide for hair loss for 3 months, presented with deep jaundice. She developed hepatic encephalopathy but gradually recovered after discontinuing flutamide. Flutamide can cause fatal toxic liver injury and hence should be used with close monitoring of liver profile.
Assuntos
Adulto , Antagonistas de Androgênios/efeitos adversos , Feminino , Flutamida/efeitos adversos , Doenças do Cabelo/complicações , Humanos , Icterícia/induzido quimicamente , Falência Hepática/induzido quimicamenteAssuntos
Acantose Nigricans/tratamento farmacológico , Adolescente , Antagonistas de Androgênios/efeitos adversos , Anticoncepcionais Orais Combinados/efeitos adversos , Acetato de Ciproterona/efeitos adversos , Diabetes Mellitus/induzido quimicamente , Congêneres do Estradiol/efeitos adversos , Etinilestradiol/efeitos adversos , Feminino , Hirsutismo/tratamento farmacológico , Humanos , Hiperandrogenismo/tratamento farmacológico , Hipertensão/induzido quimicamente , Resistência à Insulina , Congêneres da Progesterona/efeitos adversos , SíndromeRESUMO
Flutamide, an oral nonsteroidal, antiandrogenic, anilid compound which inhibits the uptake and binding of androgens to nuclear receptors in the prostate, is used with or without LH-RH analogues for treatment of patients with metastatic carcinoma of the prostate. Clinically significant hepatotoxicities such as toxic hepatitis, cholestatic hepatitis, hepatic failure, and even death have rarely been reported in the English literature, but no case has been reported in Korea. A 75-year-old man with metastatic carcinoma of the prostate had taken flutamide (750 mg/day) for 7 months and suddenly developed jaundice and general weakness. The findings of blood chemistries were compatible with cholestatic hepatitis, but ultrasonography, viral marker and auto-antibody studies did not reveal any attributable causes. Histologic examination of a sono-guided liver biopsy only disclosed centrilobular cholestasis, nuclear glycogenosis and mild sinusoidal lymphocytic infiltration. Discontinuation of flutamide resulted in an almost full recovery of the patient's liver function in 2 months. We, herein, report a case of flutamide-induced acute choestatic hepatitis with a brief review of the literature.